NU-ALLOPURINOL TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ALLOPURINOL

Pieejams no:

NU-PHARM INC

ATĶ kods:

M04AA01

SNN (starptautisko nepatentēto nosaukumu):

ALLOPURINOL

Deva:

100MG

Zāļu forma:

TABLET

Kompozīcija:

ALLOPURINOL 100MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100/1000

Receptes veids:

Prescription

Ārstniecības joma:

ANTIGOUT AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0103654001; AHFS:

Autorizācija statuss:

CANCELLED (UNRETURNED ANNUAL)

Autorizācija datums:

2018-03-28

Produkta apraksts

0
PRODUCT MONOGRAPH
NU-ALLOPURINOL
ALLOPURINOL TABLETS USP
100, 200 AND 300 MG
XANTHINE OXIDASE INHIBITOR
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL STREET, UNITS 1 & 2
OCTOBER 7, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133281
1
PRODUCT MONOGRAPH
NU-ALLOPURINOL
Allopurinol Tablets USP
100, 200 and 300 mg
THERAPEUTIC CLASSIFICATION
Xanthine Oxidase Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Allopurinol is a structural analogue of hypoxanthine. Reduction in
both the serum and urinary uric
acid levels is brought about by allopurinol inhibiting the action of
xanthine oxidase, the enzyme
responsible for the conversion of hypoxanthine to xanthine and
xanthine to uric acid. Allopurinol
is metabolized to the corresponding xanthine analogue, oxypurinol,
which is also an inhibitor of
xanthine oxidase. The action of allopurinol in blocking formation of
urate differs from that of
uricosuric agents which lower the serum uric acid level by increasing
urinary excretion of uric
acid.
INDICATIONS AND CLINICAL USE
Treatment of gout, either primary, or secondary to hyperuricemia which
occurs in blood
dyscrasias and their therapy.
Treatment of primary or secondary uric acid nephropathy, with or
without accompanying signs or
symptoms of gout.
Prophylactically, to prevent tissue urate deposition or renal calculi
in patients with leukemias,
lymphomas or other malignancies, receiving antineoplastic treatment
(radiation or cytotoxic
drugs) which might induce increased uricemia levels. Also in the
therapy and prophylaxis of
2
acute urate nephropathy and resultant renal failure in patients with
neoplastic disease who are
particularly susceptible to hyperuricemia and uric acid stone
formation (especially after radiation
therapy or use of antineoplastic drugs).
Prevention of the occurrence and recurrence of uric acid stones or
gravel and renal calcium
lithiasis in patients with hyperuricemia and/or hyperuricosuria.
CONTRAINDICATIONS
Should not be given to patients who are hypersensitive to allopurinol
or who have previously
developed